End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
219.2 CNY | +3.52% | +10.33% | -32.60% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The firm trades with high earnings multiples: 25.06 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.60% | 3.09B | C- | ||
-4.55% | 14.84B | - | ||
-13.15% | 2.44B | - | ||
-8.90% | 1.52B | - | - | |
-.--% | 1.12B | - | - | |
+58.24% | 583M | - | ||
+12.77% | 246M | C | ||
-1.41% | 227M | - | - | |
+4.26% | 189M | - | ||
-.--% | 179M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 688301 Stock
- Ratings iRay Technology Company Limited